Edoardo Caporusso

Clinical researcher skilled in designing, implementing, analyzing, and disseminating clinical studies. Proficient in scientific writing, project coordination, and collaborating with multidisciplinary teams. Specialized in schizophrenia research, with a particular focus on negative symptoms, cognitive deficits, real-life functioning, and the interplay between physical and mental health.

• Date of Birth: 01/26/93
• Nationality: Italian

Best Scientific Poster - XXVII Congresso Nazionale SOPSI 2023 - Roma

• 2025, Investigating the causal pathways among psychopathological variables, cognitive impairment, and real-life functioning in people with schizophrenia
• 2024, Insight in cognitive impairment assessed with the Cognitive Assessment Interview in a large sample of patients with schizophrenia
• 2024, Advances in the understanding of the pathophysiology of schizophrenia and bipolar disorder through induced pluripotent stem cell models
• 2024, Research evidence on the management of the cognitive impairment component of the post-COVID condition: a qualitative systematic review
• 2024, Effectiveness of a social cognition remediation intervention for patients with schizophrenia: a randomized-controlled study
• 2024, Interview Versus Performance Assessment of Cognition as Predictors of Real-World Outcomes in a Large-Scale Cross-Sectional Study in Schizophrenia
• 2024, The relationship between the resting state functional connectivity and social cognition in schizophrenia: Results from the Italian Network for Research on Psychoses
• 2023, Correlations between Negative Symptoms and Cognitive Deficits in Individuals at First Psychotic Episode or at High Risk of Psychosis: A Systematic Review
• 2023, Electrophysiological Correlates of Reward Anticipation in Subjects with Schizophrenia: An ERP Microstate Study
• 2023, Cognitive Impairment after Post-Acute COVID-19 Infection: A Systematic Review of the Literature
• 2023, Chapter on "Distress psicologico e malattie da reflusso gastresofageo e laringoesofageo"
• 2023, The structure stability of negative symptoms: longitudinal network analysis of the Brief Negative Symptom Scale in people with schizophrenia
• 2023, External validation of the five domains of negative symptoms: Focus on cognition, functional capacity, and real-world functioning
• 2022, Updated perspectives on the clinical significance of negative symptoms in patients with schizophrenia
• 2022, Social Cognition Individualized Activities Lab for Social Cognition Training and Narrative Enhancement in Patients With Schizophrenia: A Randomized Controlled Study to Assess Efficacy and Generalization to Real-Life Functioning (Prot. n: NCT05130853)
• 2021, Chapter on "Gender", Oxford Textbook of Social Psychiatry (Edited by Dinesh Bhugra, Driss Moussaoui, Tom Craig)

• 02/22/24, Cognitive remediation interventions in psychosis: from home-based practice to virtual reality, XXVIII Congresso Nazionale della Società Italiana di Psicopatologia (SOPSI) - Rome
• 12/01/21, "The Chemsex Phenomenon" - Trieste

• 09/11/19, 05/21/21, 12-weeks, multicenter double-blind, placebo-controlled parallel study to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of 3 Dose levels of TAK-831 in Adjunctive Treatment of Subjects With Negative Symptoms of Schizophrenia. Sub investigator in a "Phase 2, 12-week, Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of 3 Dose levels of TAK- 831 in Adjunctive Treatment of Adult Subjects With Negative Symptoms of Schizophrenia".
• 07/22/24, Current, Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure (INTENSIFY). Subinvestigator in a multicenter RCT evaluating early-intensified (third-line) vs treatment-as-usual (second-line) strategies in schizophrenia, bipolar disorder, and major depression, aiming to improve outcomes and reduce ineffective treatment trials and associated costs.